SXL
BLUE

Summit X LLC’s bluebird bio BLUE Stock Holding History

Summit X LLC’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25,045
Closed -$122K – 256
2025
Q1 		$122K Sell
25,045
-12,599
-33% -$75.8K 0.03% 236
2024
Q4 		$314K Buy
37,644
+9,252
+33% +$80.9K 0.07% 160
2024
Q3 		$559K Sell
28,392
-731
-3% -$12.2K 0.14% 111
2024
Q2 		$577K Buy
29,123
+17,634
+153% +$353K 0.13% 114
2024
Q1 		$294K Buy
11,489
+2,541
+28% +$65.1K 0.08% 157
2023
Q4 		$247K Buy
8,948
+830
+10% +$50.6K 0.07% 164
2023
Q3 		$494K Sell
8,118
-3,004
-27% -$211K 0.16% 101
2023
Q2 		$732K Buy
11,122
+1,537
+16% +$112K 0.18% 114
2023
Q1 		$610K Buy
+9,585
New +$1.09M 0.16% 132
2022
Q4 		– Sell
-5,171
Closed -$651K – 243
2022
Q3 		$651K Buy
+5,171
New +$585K 0.19% 117

Other funds holding BLUE

Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Summit X LLC's BLUE Position: Q2 2025 in Review

Summit X LLC sold out of bluebird bio (BLUE) in Q2 2025, closing a stake of 25,045 shares — an estimated $122K sold.

Summit X LLC first reported a position in BLUE in Q3 2022 and held it in 10 quarters. The position peaked at $732K in Q2 2023. 3 funds tracked by Wall St. Rank hold BLUE as of Q2 2025.

  • Summit X LLC reported no remaining bluebird bio position as of Q2 2025 after selling out during the quarter.
  • Summit X LLC sold 25,045 bluebird bio shares in Q2 2025, an estimated $122K.
  • Summit X LLC first reported a position in bluebird bio in Q3 2022 and held it in 10 quarters.
  • Summit X LLC's bluebird bio position peaked at $732K in Q2 2023.
  • 3 funds tracked by Wall St. Rank held bluebird bio as of Q2 2025.

Based on Summit X LLC's 13F filing for Q2 2025, filed 7 Aug 2025.